Quest Partners LLC Exelixis, Inc. Transaction History
Quest Partners LLC
- $575 Billion
- Q1 2024
A detailed history of Quest Partners LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 46 shares of EXEL stock, worth $1,033. This represents 0.0% of its overall portfolio holdings.
Number of Shares
46
Previous 14,672
99.69%
Holding current value
$1,033
Previous $352 Million
99.69%
% of portfolio
0.0%
Previous 0.07%
Shares
2 transactions
Others Institutions Holding EXEL
# of Institutions
463Shares Held
247MCall Options Held
1.7MPut Options Held
1.02M-
Black Rock Inc. New York, NY34.9MShares$783 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA30.8MShares$692 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA26.7MShares$599 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.1MShares$339 Million0.56% of portfolio
-
State Street Corp Boston, MA13.1MShares$294 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $7.23B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...